Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515111 | 0.85 | GPR119 (0.57) | GPR119CYP2C9 | |
| SCHEMBL1940586 | 0.83 | SLC22A12 (0.41) | GPR119PIP4K2AACACB | |
| SCHEMBL304441 | 0.80 | NR3C1 (0.50) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12649155 | 0.80 | PIP4K2A (0.49) | GPR119CYP2C9KCNH2PIP4K2A | |
| SCHEMBL514941 | 0.80 | GPR119 (0.40) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1442019 | 0.79 | SLC22A12 (0.40) | GPR119PIP4K2A | |
| SCHEMBL12596359 | 0.79 | GPR119 (0.65) | GPR119 | |
| SCHEMBL515118 | 0.79 | SRC (0.54) | GPR119 | |
| SCHEMBL9950465 | 0.79 | SRC (0.54) | GPR119 | |
| SCHEMBL355610 | 0.79 | GPR119 (0.42) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410089-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2399914-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | GPR119, GPR4, GPR84 | GPR119 1/4885CYP2C9 1210/4885KCNH2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.